Credit Suisse upgrades Novo Nordisk, citing Ozempic and Wego

Weight-loss drug Wegovy has had a successful relaunch, while diabetes drug Ozempic has seen accelerating growth, Credit Suisse said.

Related Keywords

Denmark , Danish , Dominic Lunn , Eli Lilly Mounjaro , Novo Nordisk , Drug Administration , Credit Suisse , Novo Nordisk Both , Eli Lilly , Weight Management , Weight Loss Diets , Biotech And Pharmaceuticals , Pharmaceuticals , Eli Lilly And Co , Novo Nordiska S , Stock Markets , Investment Strategy , Business News ,